DICE THER ETFs positioned on DICE THER
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.11% | 0 M€ | 0.00% | - | |
| 0.02% | 9 M€ | +6.00% | - | |
| 0.00% | 147 M€ | +4.84% | - | |
| 0.00% | 18 M€ | +3.41% | - | |
| 0.00% | 9 M€ | -.--% | - |
DICE Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing oral therapeutics against well-validated targets in immunology. The Company's platform, DELSCAPE, is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs). The Company's therapeutic candidate, DC-806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. The Company is also developing oral therapeutic candidates targeting a4B7 integrin for the treatment of inflammatory bowel disease (IBD) and evaluating oral therapeutic candidates targeting aVB1/aVB6 integrin for the treatment of fibrosis.
Sector
-
